Ginkgo Bioworks (DNA) Competitors

Disc Medicine (NASDAQ:IRON) and Ginkgo Bioworks (NYSE:DNA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation, profitability and community ranking.

Which has stronger valuation & earnings, IRON or DNA?

Disc Medicine has higher earnings, but lower revenue than Ginkgo Bioworks. Disc Medicine is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Disc Medicine	N/A	N/A	-$76.43M	-$3.92	-13.54
Ginkgo Bioworks	$237.42M	2.09	-$892.87M	-$9.16	-0.93

Is IRON or DNA more profitable?

Disc Medicine has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -298.78%. Disc Medicine's return on equity of -25.24% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Disc Medicine	N/A	-25.24%	-23.96%
Ginkgo Bioworks	-298.78%	-58.54%	-34.24%

Which has more risk & volatility, IRON or DNA?

Disc Medicine has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500. Comparatively, Ginkgo Bioworks has a beta of 1.25, suggesting that its stock price is 25% more volatile than the S&P 500.

Does the MarketBeat Community prefer IRON or DNA?

Disc Medicine received 35 more outperform votes than Ginkgo Bioworks when rated by MarketBeat users. Likewise, 85.51% of users gave Disc Medicine an outperform vote while only 46.15% of users gave Ginkgo Bioworks an outperform vote.

Company	Underperform	Outperform
Disc Medicine	Outperform Votes 59 85.51%	Underperform Votes 10 14.49%
Ginkgo Bioworks	Outperform Votes 24 46.15%	Underperform Votes 28 53.85%

Do insiders & institutionals have more ownership in IRON or DNA?

83.7% of Disc Medicine shares are held by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are held by institutional investors. 4.2% of Disc Medicine shares are held by insiders. Comparatively, 9.7% of Ginkgo Bioworks shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Do analysts prefer IRON or DNA?

Disc Medicine presently has a consensus target price of $98.80, indicating a potential upside of 86.17%. Ginkgo Bioworks has a consensus target price of $5.77, indicating a potential downside of 32.12%. Given Disc Medicine's stronger consensus rating and higher probable upside, equities research analysts plainly believe Disc Medicine is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Disc Medicine	0 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	3.09
Ginkgo Bioworks	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

Does the media prefer IRON or DNA?

In the previous week, Disc Medicine had 9 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 10 mentions for Disc Medicine and 1 mentions for Ginkgo Bioworks. Ginkgo Bioworks' average media sentiment score of 1.54 beat Disc Medicine's score of 1.09 indicating that Ginkgo Bioworks is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Disc Medicine	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ginkgo Bioworks	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Disc Medicine beats Ginkgo Bioworks on 13 of the 18 factors compared between the two stocks.